李梦遥博士: 后疫情时代生物医药创新五大趋势 - F50全球资本峰会2021

后疫情时代生物医药创新五大趋势
Dr. Ella Li”, or “Ella Li, Ph.D.”
Partner of ZGC U.S. Fund
CEO of ZGC Capital
Dr. Ella Li the CEO of ZGC Capital and the partner of ZGC U.S. Fund, leading ZGC’s team in investment and incubator operation. She’ established and managed several VC and fund of fund, including one with portfolio funds including KPCB, Menlo, Andreessen Horowitz, Accel and Foundation Capital. She is also the founding partner of Medlabs healthcare accelerator, providing companies with funding, mentorship and key resources to transform healthcare. Dr. Li has 15+ years of experience in pharmaceutical and biotechnology sectors and has rich experiences in therapeutic investment opportunities from discovery and clinical proof-of-concept to commercialization. She also serves as board advisor, consultant and mentor for many global accelerators, incubators and VCs. Dr. Li earned her B.S. and M.S. degrees from Peking University, Ph.D. from the University of Texas Health Science Center, and finished her postdoctoral fellowship in Harvard Medical School. She has extensive publications in prestigious journals with 10+ impact factors, including Nature Communication, Cell Metabolism, JCI, PNAS, Diabetes etc.

[@wangchaoyang7698]

很好，简练，不啰嗦，赞！

[@darby1208]

5:00